Atypical hemolytic uremic syndrome
Clinical trials for Atypical hemolytic uremic syndrome explained in plain language.
Never miss a new study
Get alerted when new Atypical hemolytic uremic syndrome trials appear
Sign up with your email to follow new studies for Atypical hemolytic uremic syndrome, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can aHUS patients safely stop eculizumab? algorithm put to the test
Disease control CompletedAtypical hemolytic uremic syndrome (aHUS) is a rare disease that damages the kidneys by causing blood clots in small vessels. The drug eculizumab blocks the complement system and has greatly reduced kidney failure, but doctors do not know how long patients should stay on it. This…
Matched conditions: ATYPICAL HEMOLYTIC UREMIC SYNDROME
Phase 4 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill shows promise for rare blood disorder aHUS
Disease control CompletedThis study tested a new oral medication called iptacopan in 34 adults with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots, low platelets, and kidney damage. The goal was to see if the drug could improve blood counts and kidney function w…
Matched conditions: ATYPICAL HEMOLYTIC UREMIC SYNDROME
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Egyptian hospitals uncover the hidden toll of a rare kidney disease
Knowledge-focused CompletedThis study reviews medical records of 200 people diagnosed with a rare blood and kidney disease called aHUS in Egyptian hospitals. Researchers want to learn about patient symptoms, treatments, and long-term health to help doctors diagnose and manage the disease better. No new tre…
Matched conditions: ATYPICAL HEMOLYTIC UREMIC SYNDROME
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC